Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
MGTA Magenta Therapeutics, Inc. daily Stock Chart
MGTA [NASD]
Magenta Therapeutics, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-2.13 Insider Own1.80% Shs Outstand39.36M Perf Week-7.53%
Market Cap347.24M Forward P/E- EPS next Y-2.08 Insider Trans-18.99% Shs Float33.06M Perf Month-1.67%
Income-81.90M PEG- EPS next Q-0.54 Inst Own72.70% Short Float3.62% Perf Quarter-24.83%
Sales- P/S- EPS this Y33.80% Inst Trans-3.47% Short Ratio6.37 Perf Half Y-28.71%
Book/sh3.19 P/B2.77 EPS next Y4.60% ROA-48.30% Target Price- Perf Year-42.37%
Cash/sh3.32 P/C2.66 EPS next 5Y- ROE-53.90% 52W Range5.76 - 16.87 Perf YTD-41.69%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-47.60% Beta-
Dividend %- Quick Ratio10.50 Sales past 5Y- Gross Margin- 52W Low53.47% ATR0.89
Employees70 Current Ratio10.50 Sales Q/Q- Oper. Margin- RSI (14)49.61 Volatility8.03% 10.40%
OptionableYes Debt/Eq0.00 EPS Q/Q-14.50% Profit Margin- Rel Volume1.41 Prev Close9.19
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume188.11K Price8.84
Recom1.80 SMA20-5.00% SMA508.50% SMA200-18.67% Volume264,779 Change-3.81%
Mar-25-19Downgrade Goldman Buy → Neutral $17 → $16
Mar-15-19Initiated Raymond James Outperform
Jul-16-18Initiated Wedbush Outperform $22
Jul-16-18Initiated JP Morgan Overweight $18
Jul-16-18Initiated Goldman Buy $18
May-14-20 08:00AM  Magenta Therapeutics Presents Data at Annual Meeting of American Society of Gene and Cell Therapy Demonstrating Cells Mobilized with MGTA-145 in a Phase I Trial Are Effective in Gene Therapy Settings Business Wire
May-07-20 07:30AM  Magenta Therapeutics Reports Recent Business Highlights and First Quarter Financial Results Business Wire
May-06-20 07:00AM  Magenta Therapeutics and AVROBIO Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies Business Wire +10.62%
07:00AM  AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies Business Wire
Apr-30-20 08:00AM  Magenta Therapeutics to Host Business Update Conference Call Business Wire -9.34%
Apr-28-20 04:30PM  Magenta Therapeutics to Present Data from Across Portfolio at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting Business Wire -8.42%
Apr-17-20 08:11AM  Magenta Therapeutics Names John Davis Jr., M.D., M.P.H, M.S., Head of Research and Development Business Wire +12.07%
Apr-16-20 08:00AM  Magenta Therapeutics Provides Business Update Business Wire
Apr-07-20 01:21PM  We Think Magenta Therapeutics (NASDAQ:MGTA) Can Afford To Drive Business Growth Simply Wall St.
Mar-03-20 08:00AM  Magenta Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights Business Wire -5.36%
Feb-26-20 08:30AM  Magenta Therapeutics to Participate in Cowen Health Care Conference on Monday, March 2nd in Boston Business Wire
Feb-24-20 08:30AM  Magenta Therapeutics Completes Dosing in Phase 1 MGTA-145 Trial, Demonstrating Rapid, Single-Day First Line Stem Cell Mobilization and Collection Business Wire -9.21%
08:30AM  Magenta Conditioning Lead Clinical Candidate MGTA-117 Demonstrates Broad Tolerability and High Therapeutic Index in Non-human Primates Business Wire
Feb-20-20 08:30AM  Magenta Therapeutics Announces Updated Phase 2 Data on MGTA-456 Cell Therapy, Demonstrating Continued Durability in Inherited Metabolic Disorders Business Wire +8.21%
Feb-16-20 08:25AM  3 Monster Growth Stocks That Can Charge Forward in 2020 TipRanks
Feb-06-20 08:30AM  Magenta Therapeutics to Participate in Guggenheim Healthcare Talks Oncology Day on Thursday, February 13th in New York City Business Wire
Feb-05-20 08:30AM  Magenta Therapeutics Expands Leadership Team, Appoints Kristen Stants as Chief People Officer and Li Malmberg as Senior Vice President, Head of Manufacturing Business Wire
Jan-13-20 08:00AM  Magenta Therapeutics Advances Conditioning Platform and Clinical Programs, Highlights Recent Milestones and 2020 Goals Business Wire -10.83%
Jan-06-20 08:30AM  Magenta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th in San Francisco Business Wire
Dec-19-19 09:54PM  Did Hedge Funds Drop The Ball On Magenta Therapeutics, Inc. (MGTA) ? Insider Monkey
Dec-11-19 09:47AM  Goldman Sachs: The Good, the Bad and the Ugly of the Biotech Sector TipRanks
Dec-09-19 07:45AM  Magenta Therapeutics Demonstrates First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of Antibody-drug Conjugate Business Wire
Dec-07-19 05:30PM  First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers Business Wire
08:35AM  The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling Benzinga
Dec-01-19 09:30AM  The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More Benzinga
Nov-26-19 04:05PM  Magenta Therapeutics to Present at the Evercore ISI HealthCONx Conference on Tuesday, December 3rd Business Wire -6.06%
Nov-13-19 08:00AM  Magenta Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights Business Wire
Nov-11-19 08:30AM  Magenta Therapeutics Presents First Immune Reset Results with Antibody-Drug Conjugate Across Multiple Autoimmune Diseases at ACR Business Wire
Nov-06-19 09:00AM  Magenta Therapeutics to Present New Clinical and Preclinical Data at American Society of Hematology (ASH) Annual Meeting Business Wire
Oct-30-19 09:31AM  Magenta Therapeutics, Inc. (MGTA) Is Burning These Hedge Funds Insider Monkey +8.66%
Oct-16-19 08:30AM  Magenta Therapeutics Appoints Jan Pinkas as Senior Vice President, Head of Translational Sciences and Announces Transition of Chief Scientific Officer Business Wire -6.90%
Oct-09-19 08:14AM  Magenta Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks
Oct-08-19 09:56AM  Did Magenta Therapeutics, Inc. (NASDAQ:MGTA) Insiders Sell Shares? Simply Wall St.
Sep-04-19 08:30AM  Magenta Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to MGTA-456 for the Treatment of Inherited Metabolic Disorders Business Wire
Aug-08-19 08:00AM  Magenta Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights Business Wire +11.10%
Aug-06-19 08:30AM  Magenta Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 13th Business Wire
Jul-12-19 02:29PM  CORRECTING and REPLACING Magenta Therapeutics Appoints Anne McGeorge to Board of Directors Business Wire
Jun-24-19 04:05PM  Magenta Therapeutics Appoints Anne McGeorge to Board of Directors Business Wire -7.47%
Jun-22-19 07:57AM  Can You Imagine How Magenta Therapeutics's (NASDAQ:MGTA) Shareholders Feel About The 12% Share Price Increase? Simply Wall St.
Jun-06-19 04:05PM  Magenta Therapeutics to Present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11th Business Wire
May-09-19 08:00AM  Magenta Therapeutics Reports First Quarter 2019 Financial Results and Recent Business Highlights Business Wire
07:30AM  Magenta Therapeutics Presents Updated Phase 2 Clinical Data on MGTA-456 Cell Therapy at American Academy of Neurology Annual Meeting Business Wire
May-06-19 04:05PM  Magenta Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
May-01-19 08:11PM  Magenta Therapeutics Announces Pricing of Public Offering Business Wire
Apr-29-19 04:32PM  Magenta Therapeutics Launches Proposed Public Offering Business Wire
08:00AM  Magenta Therapeutics to Present Preclinical Data on E478 Stem Cell Gene Therapy Expansion Program at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy Business Wire
Apr-24-19 08:30AM  Magenta Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of MGTA-145, a First-Line Stem Cell Mobilization Product Candidate Business Wire +5.54%
Apr-07-19 06:00PM  3 Stocks That Have More Than Tripled So Far in 2019 Motley Fool
Mar-20-19 12:07PM  Raymond James Thinks Magenta Still Has Upside GuruFocus.com
Mar-19-19 07:30AM  Magenta Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights Business Wire
Mar-15-19 01:32PM  How Many Insiders Bought Magenta Therapeutics, Inc. (NASDAQ:MGTA) Shares? Simply Wall St. +26.19%
Mar-06-19 04:05PM  Magenta Therapeutics to Present at Investor Conferences in March Business Wire
Feb-25-19 08:15AM  Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs, Including First Conditioning Development Candidate Business Wire +12.03%
08:15AM  Magenta Therapeutics Presents Clinical and Preclinical Data on MGTA-456 Cell Therapy in Best Abstracts Sessions at Transplant and Cellular Therapy (TCT) Annual Meeting Business Wire
Feb-21-19 08:00AM  Magenta Therapeutics Presents Preclinical Data on MGTA-145, First-Line Stem Cell Mobilization Product Candidate for Autologous and Allogeneic Bone Marrow Transplant Business Wire -5.66%
Feb-07-19 08:30AM  Magenta Therapeutics to Present at Guggenheim Healthcare Investor Conference Business Wire
Jan-02-19 08:30AM  Magenta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 Business Wire +5.26%
Dec-02-18 09:00PM  Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs Demonstrating Potent Stem Cell Depletion and Anti-Leukemia Survival Benefit Business Wire
09:00PM  Magenta Therapeutics Presents New Data from Phase 2 Study of MGTA-456 Cell Therapy in Patients with Inherited Metabolic Disorders Business Wire
Dec-01-18 12:30PM  Magenta Therapeutics Presents New Preclinical Data on MGTA-145 Stem Cell Mobilization Product Candidate Business Wire
Nov-26-18 08:30AM  Magenta Therapeutics to Host Webcast of Investor and Analyst Event During ASH Business Wire
Nov-19-18 08:00AM  Magenta Therapeutics Appoints Jason Ryan as Chief Operating and Financial Officer Business Wire
Nov-08-18 08:00AM  Magenta Therapeutics Reports Recent Operational Progress and Third Quarter 2018 Financial Results Business Wire
Nov-01-18 09:00AM  Magenta Therapeutics Announces Acceptance of Nine Abstracts Covering Clinical and Preclinical Data at ASH, Representing Progress across the Portfolio of Conditioning, Stem Cell Mobilization and Expansion Programs Business Wire -5.82%
Sep-24-18 08:30AM  Magenta Therapeutics Added to Russell 2000 and 3000 Indexes Business Wire +5.92%
Aug-09-18 04:05PM  Magenta Therapeutics Reports Recent Operational Progress and Second Quarter 2018 Financial Results Business Wire
Aug-08-18 04:05PM  Magenta Therapeutics to Present at Wedbush PacGrow Healthcare Conference Business Wire
Jul-25-18 07:40AM  Breakfast Technical Briefing on Neptune Technologies & Bioressources and Three Other Additional Biotech Stocks ACCESSWIRE
Jul-16-18 12:33PM  Wedbush Bets On Magenta Therapeutics, Projects Rewards If Stem Cell Technology Successful Benzinga
Jul-03-18 06:23AM  Goodwin dominates this years record batch of Mass. biotech IPOs American City Business Journals
Jun-25-18 04:05PM  Magenta Therapeutics Announces Closing of Initial Public Offering Business Wire
Jun-21-18 11:41AM  [$$] Banner Day for Biotech as Five Drug Developers Go Public The Wall Street Journal
Jun-20-18 10:01PM  [$$] Eidos Therapeutics Goes Public, Joining Biotech IPO Flurry The Wall Street Journal
03:11PM  8 Biotech Stocks With IPOs This Week InvestorPlace
Jun-18-18 01:36PM  Don't Fear This Burst of Biotech IPOs Bloomberg
Jun-17-18 04:22PM  The IPO Outlook For The Week Of June 18: Pharma, Pharma And More Pharma Benzinga
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. Thecompany is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. It has a has a research and clinical collaboration agreement with AVROBIO, Inc.to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GARDNER JASONSee RemarksJan 10Sale15.2511,200170,800251,212Jan 10 05:01 PM
DAVIS JOHN C. JRChief Medical OfficerJan 02Option Exercise9.4911,294107,18019,598Jan 03 04:01 PM
GARDNER JASONSee RemarksJan 02Sale15.102,80042,280262,412Jan 03 04:01 PM
DAVIS JOHN C. JRChief Medical OfficerJan 02Sale15.0411,294169,8178,304Jan 03 04:01 PM
ZDRAVESKI ZORANSee RemarksDec 24Sale16.007,902126,432128,009Dec 26 04:11 PM
ISACSON CHRISTINA K.Chief Business OfficerDec 24Sale16.014,46371,45383,786Dec 26 04:12 PM
ISACSON CHRISTINA K.Chief Business OfficerDec 23Sale16.039,867158,16888,249Dec 26 10:12 AM
ZDRAVESKI ZORANSee RemarksDec 23Sale16.034,18167,021135,911Dec 26 10:13 AM
GARDNER JASONSee RemarksDec 23Sale15.102,89743,755265,212Dec 23 04:41 PM
DAVIS JOHN C. JRChief Medical OfficerDec 20Option Exercise9.499198,7219,223Dec 20 05:52 PM
GARDNER JASONSee RemarksDec 20Sale15.1676,7111,162,617268,109Dec 20 06:22 PM
DAVIS JOHN C. JRChief Medical OfficerDec 20Sale15.0091913,7858,304Dec 20 05:52 PM
DAVIS JOHN C. JRChief Medical OfficerDec 10Option Exercise9.4917,055161,85225,359Dec 11 04:03 PM
DAVIS JOHN C. JRChief Medical OfficerDec 10Sale15.0017,055255,8258,304Dec 11 04:03 PM
GARDNER JASONSee RemarksDec 10Sale15.104,39266,319344,820Dec 13 05:08 PM
DAVIS JOHN C. JRChief Medical OfficerDec 09Option Exercise9.494,61443,78712,918Dec 11 04:03 PM
DAVIS JOHN C. JRChief Medical OfficerDec 09Sale15.004,61469,2108,304Dec 11 04:03 PM
COOKE MICHAEL P.Chief Scientific OfficerDec 02Sale13.007,50097,520240,523Dec 02 08:29 PM
COOKE MICHAEL P.Chief Scientific OfficerNov 20Sale12.005,00060,000248,023Nov 25 08:52 PM
open in yahoo | open in reuters | open in google